<DOC>
	<DOC>NCT01785771</DOC>
	<brief_summary>An 39-week plus extensions, open-label study to estimate the reduction in HbA1c in patients with initial HbA1c &gt;10% &lt;/=12% who are treated with ITCA 650 20 mcg/day for 13 weeks followed by ITCA 650 60 mcg/day for 26 weeks plus optional 26-week extensions with continued treatment with ITCA 650 60 mcg/day</brief_summary>
	<brief_title>A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Men or women age 18 to 80 years with type 2 diabetes On stable treatment regimen of diet and exercise alone or in combination with a stable &amp; optimal or nearoptimal dose of metformin, sulfonylurea, TZD or combination of these drugs HbA1c &gt;10.0% and â‰¤12.0% Prior treatment with any GLP1 receptor agonist History of hypersensitivity to exenatide or liraglutide FPG &gt;300 mg/dL History of medullary thyroid cancer or a family or personal history of multiple endocrine neoplasia type 2 Taking DPP4 inhibitors, incretin mimetics, alpha glucosidase inhibitors, meglitinides or insulin within last 3 months history of pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>